All News

Individuals who had experienced a concussion were found to be at a greater risk of Parkinson disease, mood and anxiety disorders (MADs), dementia, and hyperactivity disorder, with concussed women indicated as a notable at-risk population for MADs, according to study findings published today.

A comprehensive review of all safety-related label modifications of vaccines approved by the FDA between January 1996 and December 2015 found that vaccines are “remarkably safe” and confirmed population vaccination as a major public health strategy.

In patients with episodic migraine, erenumab provided sustained efficacy for the condition over the course of 1 year, according to new results from a study to evaluate the efficacy and safety of erenumab in migraine prevention (STRIVE), published in Neurology.

Researchers interviewed US specialists in an effort to see how conscious and unconscious thoughts about race and gender contributed to an unequal allocation of various treatments for heart failure.

In beginning the first phase 3 clinical trial to examine a vaccine candidate for the coronavirus disease 2019 (COVID-19), Moderna Inc announced that the Trump administration increased funding to expand the trial to 30,000 US participants; employers have considered and some have made it a requirement for employees to sign a waiver to not sue the organization if they are infected by COVID-19 or suffered any injury while working; study finds 1 flu shot can reduce the risk for Alzheimer disease by 17% and 1 pneumonia vaccine before age 75 can reduce the risk by 25%.

Alemtuzumab did not appear to negatively impact pregnancy outcomes in women who took the therapy for relapsing-remitting multiple sclerosis prior to becoming pregnant.

Having health insurance, a higher level of education, and more money were associated with a greater likelihood of caregivers disclosing their HIV status in the community, either positive or negative, while being male and living in a rural location indicated a lesser likelihood, reports AIDS Research and Therapy.

Assessing the value of novel therapies has been challenging and controversial using existing methods, pointing to the need for continued exploration of new approaches.

Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, presented the latest round of data from REDUCE-IT at the American Society of Preventive Cardiology Virtual Summit 2020 this morning

In the last 3 months of life, health care costs were significantly lower for patients receiving multidisciplinary collaborative care than for patients receiving specialized care or nonspecialized care. The differences in costs were primarily driven by differences in hospitalizations and emergency department visits.

In children with inflammatory rheumatic diseases, tocilizumab can cause serious adverse events (AEs), with children who were younger at disease onset and at time of tocilizumab initiation especially affected.

Just when renal replacement therapy should start after acute kidney injury has been debated.

The orders President Trump signed Friday include a deadline for the pharmaceutical industry to come up with their own plan by August 24 to lower prices.

The therapy, to be sold as Tecartus, will be used to treat adult patients with mantle cell lymphoma who have relapsed or not responded to other treatments.

IQVIA, a health information technology and clinical research company, recently announced a new collaboration with JDRF, the world’s largest nonprofit funder of type 1 diabetes (T1D) research. Together, the companies plan to develop a real-world research platform to facilitate evidence generation for T1D via non-identified patient-level data and analytics.

A recent webinar discussed what causes symptom recurrence in patients with Parkinson disease and what implications this has for health outcomes and health care cost.

Using a computational algorithm, researchers at Children's Hospital of Philadelphia analyzed noncoding genetic mutations to discover how they factor into 5 pediatric cancers.

The researchers noted that these results can help inform therapeutic decision making and identify opportunities to address barriers to disease-modifying drug (DMD) adherence, which not only improves clinical outcomes but also reaps benefits when it comes to health care costs.

This week, the top managed care news included states suing the Trump administration over an HHS rule on nondiscrimination; experimental vaccines show promise against COVID-19 in healthy subjects; diagnostic delays from COVID-19 may increase cancer-related deaths.

Intensity of headache pain is as important as frequency when evaluating the clinical response and impact of migraine preventive treatment with OnabotulinumtoxinA on patient headache-related disability, according to a recent study.

The health burden of comorbid chronic obstructive pulmonary disease (COPD) and asthma is known to be greater than when either condition exists on its own. An upcoming study shows that COPD is linked with greater all-cause mortality and greater risk of mortality in patients with coexisting asthma who also had long-term use of corticosteroids.

New CDC data outline the prevalence of 5 common underlying health conditions that exacerbate coronavirus disease 2019 (COVID-19) symptoms; the FDA announced information regarding naloxone must be included on labels for opioids and opioid use disorder medications; despite a district judge's ruling nearly a month ago, hundreds of migrant detainees are being held in detention centers in states where COVID-19 cases are surging.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Experts surveyed regarding how best to treat patients with chronic lymphocytic leukemia (CLL) amid the pandemic agreed with social distancing, but were cautious about universal testing and treatment continuation.

A new study may have uncovered reasons why some patients with multiple myeloma have poor outcomes following allogeneic stem cell transplantation.

A phase 3 study of ruxolitinib (Jakafi) has met its primary end point of superior overall response rate (ORR) compared with the best available therapy in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD).

While clinical guidelines call for those with diabetes to be tested regularly for kidney disease, less than 50% of these patients are tested once a year, according to the National Kidney Foundation.